WuXi Biologics to Grow Its DS/DP Capacity in Singapore

WuXi Biologics, a contract research, development, and manufacturing organization (CRDMO), has announced a 10-year, $1.4 billion investment plan to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. This new site will add 120,000L of biomanufacturing capacity to WuXi Biologics’ global network by 2026 and is anticipated to employ 1,500 research, development, and manufacturing staff when complete.

According to the CRDMO, this aforementioned new addition in Singapore is expected to become a key part of the global supply chain network the company has established to meet clients’ needs. The center will also reinforce WuXi Biologics’ "global dual sourcing" strategy, which ensures that customer projects can be fulfilled at multiple facilities globally to mitigate potential risks.

“Singapore has established itself as one of the most advanced pharmaceutical hubs in the world,” notes Chris Chen, PhD, CEO of WuXi Biologics. “As a trusted partner to global healthcare companies and a strong contributor to the local community, WuXi Biologics’ investment in the new CRDMO center will enhance the sustainable growth and success of the Singapore biotech ecosystem, and enable the global biologics industry with a more robust supply chain. … WuXi Biologics looks forward to moving ahead with this important project to enable global partners and benefit patients worldwide.”